Isomorphic Labs raises $5 billion to take AI-designed drugs toward clinical trials

The Alphabet drug-discovery unit's Series C was co-led by Greenoaks and Sequoia, with Andreessen Horowitz joining as a new investor.
Why it matters
Isomorphic was spun out of DeepMind to turn AlphaFold-style protein modelling into medicines. The new money is meant to move its own candidates into human trials, a step no AI-first drug company has yet turned into an approved drug. It also has partnerships with Eli Lilly, Novartis and Johnson & Johnson.
Key facts
- $5 billion Series C
- Co-led by Greenoaks and Sequoia; a16z is new
- Backers include GV, Thrive, MGX and Temasek
- Partnerships with Eli Lilly, Novartis and J&J